ArticleBMJ (Clinical research ed.)2023
Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.
Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
203 citing papers in PubMed, 8 syntheses or guidelines pooled it, 349 citations in OpenAlex.
- Risk of new diagnoses and exacerbations of chronic conditions after SARS-CoV-2 infection: a systematic review update.Epidemiologic reviews · 2026Pooled it
- Evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition: an updated living systematic review.Epidemiology and infection · 2025Pooled it
- Gender Disparities in Neurological Symptoms of Long COVID: A Systematic Review and Meta-Analysis.Neuroepidemiology · 2025Pooled it
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Definition and measurement of post-COVID-19 conditions in real-world practice: a global systematic literature review.BMJ open · 2024Pooled it
- The burden of persistent symptoms after COVID-19 (long COVID): a meta-analysis of controlled studies in children and adults.Virology journal · 2024Pooled it
- Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Pooled it
- Pooled it
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Dynamic changes in cardiac autonomic function persist in the postacute phase after SARS-CoV-2 infection in a hamster model of COVID-19.Heart rhythm O2 · 2026Article
- Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review.Journal of clinical medicine · 2026Review
- Observational
- Incident diabetes within the first two years after SARS-CoV-2 infection: a population-based retrospective cohort study of the Agency for Health Protection of Milan, Italy.BMC infectious diseases · 2026Article
- Distinct plasma proteome signature at 3 months post-COVID-19 infection irrespective of post-COVID condition.Scientific reports · 2026Article
- Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases.Journal of clinical medicine · 2026Article
- Long-COVID: assessment of circulating markers suggests no cerebral neuronal damage, neuroinflammation or systemic inflammation-a controlled study.Scientific reports · 2026Article
- Associations of selective serotonin reuptake inhibitors and long COVID risk in patients with depression: a retrospective cohort study.Infection · 2026Article
- Is long-term disruption of the renin-angiotensin-aldosterone system associated with long COVID? A retrospective cohort study among healthcare workers.BMC infectious diseases · 2026Article
- Excess primary healthcare consultations in Norway in 2024 compared to pre-COVID-19-pandemic baseline trends.Archives of public health = Archives belges de sante publique · 2026Article
- The Time Course of Serum Iron and Serum Ferritin Concentrations Post-COVID-19 and Influenza Vaccinations.Case reports in infectious diseases · 2026Article
143 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status.
designRetrospective nationwide cohort study.
settingElectronic medical records from an Israeli nationwide healthcare organisation. POPULATION: 1 913 234 Maccabi Healthcare Services members of all ages who did a polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 1 October 2021.
main outcome measuresRisk of an evidence based list of 70 reported long covid outcomes in unvaccinated patients infected with SARS-CoV-2 matched to uninfected people, adjusted for age and sex and stratified by SARS-CoV-2 variants, and risk in patients with a breakthrough SARS-CoV-2 infection compared with unvaccinated infected controls. Risks were compared using hazard ratios and risk differences per 10 000 patients measured during the early (30-180 days) and late (180-360 days) time periods after infection.
resultsCovid-19 infection was significantly associated with increased risks in early and late periods for anosmia and dysgeusia (hazard ratio 4.59 (95% confidence interval 3.63 to 5.80), risk difference 19.6 (95% confidence interval 16.9 to 22.4) in early period; 2.96 (2.29 to 3.82), 11.0 (8.5 to 13.6) in late period), cognitive impairment (1.85 (1.58 to 2.17), 12.8, (9.6 to 16.1); 1.69 (1.45 to 1.96), 13.3 (9.4 to 17.3)), dyspnoea (1.79 (1.68 to 1.90), 85.7 (76.9 to 94.5); 1.30 (1.22 to 1.38), 35.4 (26.3 to 44.6)), weakness (1.78 (1.69 to 1.88), 108.5, 98.4 to 118.6; 1.30 (1.22 to 1.37), 50.2 (39.4 to 61.1)), and palpitations (1.49 (1.35 to 1.64), 22.1 (16.8 to 27.4); 1.16 (1.05 to 1.27), 8.3 (2.4 to 14.1)) and with significant but lower excess risk for streptococcal tonsillitis and dizziness. Hair loss, chest pain, cough, myalgia, and respiratory disorders were significantly increased only during the early phase. Male and female patients showed minor differences, and children had fewer outcomes than adults during the early phase of covid-19, which mostly resolved in the late period. Findings remained consistent across SARS-CoV-2 variants. Vaccinated patients with a breakthrough SARS-CoV-2 infection had a lower risk for dyspnoea and similar risk for other outcomes compared with unvaccinated infected patients.
conclusionsThis nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.